These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22144567)

  • 21. Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment?
    Burgers LT; Nauta ST; Deckers JW; Severens JL; Redekop WK
    Int J Cardiol; 2014 Oct; 176(3):980-7. PubMed ID: 25217221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
    van Hout BA; Simoons ML
    Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
    Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D
    Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of statins in coronary heart disease.
    Franco OH; Peeters A; Looman CW; Bonneux L
    J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
    Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
    Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP; Visseren FL; de Wit GA; Algra A
    BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease.
    Garber AM; Solomon NA
    Ann Intern Med; 1999 May; 130(9):719-28. PubMed ID: 10357690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.
    Scuffham PA; Chaplin S
    Pharmacoeconomics; 2004; 22(8):525-35. PubMed ID: 15217308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States.
    Mitchell AP; Simpson RJ
    BMC Res Notes; 2012 Jul; 5():373. PubMed ID: 22828389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
    Lazar LD; Pletcher MJ; Coxson PG; Bibbins-Domingo K; Goldman L
    Circulation; 2011 Jul; 124(2):146-53. PubMed ID: 21709063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective].
    Klever-Deichert G; Hinzpeter B; Wendland G; Lauterbach K
    Med Klin (Munich); 2000 Jun; 95(6):305-13. PubMed ID: 10935414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness.
    Ho WK; Hankey GJ; Eikelboom JW
    Expert Opin Pharmacother; 2004 Mar; 5(3):493-503. PubMed ID: 15013918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
    Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
    Main C; Palmer S; Griffin S; Jones L; Orton V; Sculpher M; Henderson R; Sudlow C; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(40):iii-iv, xv-xvi, 1-141. PubMed ID: 15461878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing statin treatment for primary prevention of coronary artery disease.
    Hayward RA; Krumholz HM; Zulman DM; Timbie JW; Vijan S
    Ann Intern Med; 2010 Jan; 152(2):69-77. PubMed ID: 20083825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
    Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
    Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with healthcare utilization costs for statin therapy--a pilot study in Hong Kong.
    Cheng CW; Chan JC; Tomlinson B; Woo KS; You JH
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):484-8. PubMed ID: 17063979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.